Investment Thesis
Anebulo Pharmaceuticals is a pre-revenue pharmaceutical company with significant ongoing losses and negative cash flow, indicating it is in early-stage development without commercial operations. The company's financial viability depends entirely on successful drug development and future revenue generation, with current burn rate consuming approximately 29% of cash reserves annually.
ANEB Strengths
- Strong liquidity position with $9.0M cash representing 95.7% of total assets
- Minimal debt burden with zero long-term debt and low liabilities ($1.5M)
- Excellent current/quick ratios (31.63x) providing substantial runway for operations
ANEB Risks
- No revenue generation indicating company has not achieved commercialization of any products
- Persistent operating losses of $4.9M with negative net income of $4.2M
- Negative free cash flow of $2.6M annually creating material runway depletion risk; at current burn rate, cash reserves depleted in approximately 3.5 years without additional funding
- Extreme negative ROE (-52.4%) and ROA (-44.1%) demonstrating value destruction
- Zero insider transactions in last 90 days suggesting lack of management confidence or activity
- High execution risk inherent to pharmaceutical development stage companies with binary outcomes
Key Metrics to Watch
- Operating cash burn rate and cash runway duration
- Clinical trial progress and regulatory milestones for pipeline programs
- Equity financing activities and capital raise announcements
- Path to revenue generation and product commercialization timeline
- Changes in insider ownership and executive compensation structure
ANEB Financial Metrics
ANEB Profitability Ratios
ANEB Balance Sheet & Liquidity
ANEB 5-Year Financial Trend
5-Year Trend Summary: Anebulo Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.32 indicates the company is currently unprofitable.
ANEB Growth Metrics (YoY)
ANEB Capital Allocation
ANEB SEC Filings
Access official SEC EDGAR filings for Anebulo Pharmaceuticals, Inc. (CIK: 0001815974)